display ongoing
results: demonstrated suggested inconclusive safety concern ongoing study
metastatic/advanced NSCLC (mNSCLC) - 1st line (L1)
squamous - mNSCLC - L1 - all population
anti-CTLA-4
ipilimumab based treatment
ipilimumab plus SoC CA184-104

Study type:

 

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons